ArticleOncotarget2014

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.

Siti Norasikin Mohd Nafi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.